Mechanistically, blockade of PD-1/PD-L1 interactions can to a certain extent restore the functions of exhausted T cells with high expression of PD-1, resulting in enhanced anti-tumor immunity [33, 34]. The gene discussed is PDCD1; the disease is neoplasm.